<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Vasopressors • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Vasopressors • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/vasopressors/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/vasopressors/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="vasopressors" tabindex="-1">vasopressors</h1>
<ul>
<li>related: <a href="/wiki/notes/Medicine/">Medicine</a>, <a href="/wiki/notes/ICU/">ICU</a></li>
</ul>
<h2 id="overview" tabindex="-1">Overview</h2>
<p>The table below categorizes vasoactive medications.  This might seem like a lot, but grouping drugs together into classes can simplify things.</p>
<p><img src="https://i0.wp.com/emcrit.org/wp-content/uploads/2020/02/pressortable.jpg?resize=750%2C657&amp;ssl=1" alt=""></p>
<p><img src="https://i2.wp.com/emcrit.org/wp-content/uploads/2016/03/midodrinemap.png?resize=400%2C305" alt=""></p>
<h3 id="inodilators" tabindex="-1">inodilators</h3>
<ul>
<li>Inodilators
<ul>
<li>increase inotropy and vasodilates</li>
<li>cardiac output increases</li>
<li>blood pressure variable</li>
<li>If heart responds strongly, bp increases. If heart is already working as hard as posible, vasodilation takes over</li>
<li>cardiogenic shock: good use but difficult with hypotensive patients</li>
<li>septic shock: can use if cardiac output low but can be difficult with blood pressure</li>
<li>titrate against cardiac output and not blood pressure</li>
</ul>
</li>
<li>Dobutamine
<ul>
<li>beta receptor</li>
<li>Increase inotropy but vasocilates</li>
<li>shorter half life, easier titration</li>
<li>desensitization long term</li>
</ul>
</li>
<li>Milrinone
<ul>
<li>Increase CAMP</li>
<li>more vasodilation, better for cardiogenic shock</li>
<li>renally eliminated</li>
</ul>
</li>
<li>isoproterenol
<ul>
<li>pure b1 b2</li>
<li>Very powerful chronotrope, some inotropic</li>
<li>use for bradycardia</li>
<li>titrate against heart rate</li>
<li>no vasoconstriction so can give peripherally</li>
<li>expensive</li>
</ul>
</li>
</ul>
<h3 id="pure-vasopressors" tabindex="-1">pure vasopressors</h3>
<h5 id="vasopressin" tabindex="-1"><strong>vasopressin</strong></h5>
<ul>
<li>Mechanism: Stimulates V1 and V2 receptors, causing vasoconstriction and renal water retention.</li>
<li>Physiologic effects:
<ul>
<li>It increases systemic vascular resistance (SVR).</li>
<li>It does cause venoconstriction, which may increase preload.</li>
<li>Its dominant effect on cardiac output is often to cause a reduction (but this may depend on the heart's ability to tolerate increased afterload).</li>
</ul>
</li>
<li>Clinical use:
<ul>
<li>Vasodilatory shock (particularly sepsis).  Typically given in low doses (0-0.06 U/min), either as primary or secondary agent (27483065).</li>
<li>Front-line agent for hepato-renal syndrome (HRS) in countries lacking terlipressin (such as the United States).</li>
<li>Central diabetes insipidus (very low doses needed, e.g. 0.01 units/minute or less).</li>
<li>Variceal gastrointestinal hemorrhage (theoretically an attractive agent, but pragmatically it's impossible to titrate adequately).</li>
</ul>
</li>
<li>How to titrate: typically, against blood pressure.</li>
<li>Pro/Con
<ul>
<li>Vasopressin may preferentially cause vasoconstriction of post-glomerular arterioles in the kidney, causing improvement in renal function.</li>
<li>It may cause some pulmonary vasodilation, which can be helpful in the context of pulmonary hypertension.</li>
<li>Vasopressin shouldn't generally be given peripherally (if it extravasates, there is no antidote).</li>
<li>Vasopressin can cause digital ischemia, especially when combined with norepinephrine – <strong>must pay careful attention to perfusion of hands and feet; shut off vasopressin at first sign of ischemic digits</strong>.</li>
</ul>
</li>
</ul>
<h5 id="phenylephrine" tabindex="-1"><strong>phenylephrine</strong></h5>
<ul>
<li>Mechanism:  Pure alpha-agonist, causes arterial and venous vasoconstriction.</li>
<li>Physiologic effect
<ul>
<li>Increased systemic vascular resistance (SVR).</li>
<li>Venoconstriction increases the <em>preload</em>.</li>
<li>Effect on cardiac output depends on preload-responsiveness versus ability of the heart to handle increased afterload.   For example, in a patient with systolic heart failure and volume overload, added preload won't help, whereas the heart may be unable to tolerate afterload – so the net effect is to reduce the cardiac output. Alternatively, for a patient who is preload-responsive with a stronger ejection fraction, phenylephrine could cause a net <em>increase</em> in cardiac output.</li>
<li>Available evidence in sepsis suggests that phenylephrine has a very similar physiologic effect compared to norepinephrine.  Both agents are predominantly alpha-agonists.</li>
<li>Phenylephrine can cause a mild reflex bradycardia due to elevation in blood pressure.</li>
</ul>
</li>
<li>Clinical use:
<ul>
<li>Vasodilatory shock.</li>
<li>Useful in patients with critical aortic stenosis (who have a <em>fixed</em> afterload imposed on the left ventricle by the stenotic valve).</li>
<li>Atrial fibrillation with fast ventricular response (increases blood pressure while causing reflex reduction in heart rate).</li>
</ul>
</li>
<li>How to titrate: typically, against blood pressure.</li>
<li>Can also be used as sticks, Neo-synephrine, 10mg/ml, onset 1 min, half life 5 min</li>
<li>Pro/Con
<ul>
<li>It has classically been feared that phenylephrine would drop the cardiac output.  This seems to occur with phenylephrine <em>boluses</em>, but not with <em>infusions</em> (available evidence indicates that a phenylephrine infusion functions pretty similarly compared to a norepinephrine infusion).</li>
<li>It is safe to give peripherally.</li>
<li>Phenylephrine is about ten times less potent than norepinephrine (i.e. 10 mcg/min phenylephrine is roughly equivalent to 1 mcg/min norepinephrine).  Phenylephrine is generally supplied as a fairly <em>dilute</em> solution, which can make this logistically problematic for patients requiring high-dose vasoconstriction.  Thus, phenylephrine monotherapy is largely restricted to patients with mild to moderate vasodilatory shock due to logistic constraints.</li>
</ul>
</li>
</ul>
<h3 id="inopressors" tabindex="-1">inopressors</h3>
<h5 id="norepinephrine" tabindex="-1"><strong>norepinephrine</strong></h5>
<ul>
<li>Mechanism:Predominantly an alpha-agonist, with some beta-agonism as well.</li>
<li>Physiology
<ul>
<li>Increases systemic vascular resistance (SVR), causes venoconstriction (increasing preload), and has an inotropic/chronotropic effect.</li>
<li>Increases blood pressure and may increase urine output.</li>
<li>Tends to cause cardiac output to increase or remain stable (depending on how responsive the heart is to preload, afterload, and inotropy).</li>
</ul>
</li>
<li>Clinical use
<ul>
<li>Widely popular first-line agent for a variety of shock states (septic shock, cardiogenic shock with severe hypotension).</li>
<li>Good “broad spectrum” vasoactive agent when it's unclear precisely what is going on.</li>
</ul>
</li>
<li>How to titrate:
<ul>
<li>Typically, against blood pressure.</li>
<li><a href="https://emcrit.org/pulmcrit/high-dose-vasopressor/">There is no “maximal dose”</a> of norepinephrine.</li>
</ul>
</li>
<li>Pro/Con
<ul>
<li>Strong track record in septic and cardiogenic shock.</li>
</ul>
</li>
</ul>
<h5 id="epinephrine" tabindex="-1"><strong>epinephrine</strong></h5>
<ul>
<li>Mechanism:  At lower doses the beta-agonist effects may predominate; with ongoing up-titration there are increasing alpha-agonist effects as well.</li>
<li>Physiology
<ul>
<li>Causes chronotropy and inotropy, thereby increasing the cardiac output.</li>
<li>Increases systemic vascular resistance and also causes venoconstriction (increasing preload).</li>
<li>Stabilizes mast cells, blocking the pathophysiology of anaphylaxis.</li>
<li>Beta-2 agonist stimulation causes bronchodilation, decreases potassium levels, and stimulates the generation of <em>aerobic lactate production</em> by the liver.  This is often feared, but lactate may be used as a metabolic fuel by the heart, so this mechanism of action is <a href="https://emcrit.org/pulmcrit/understanding-lactate-in-sepsis-using-it-to-our-advantage/">probably beneficial</a> (in the absence of profound pre-existing metabolic acidosis).</li>
</ul>
</li>
<li>Clinical uses
<ul>
<li>Bradycardia and bradycardic shock (given inotropic effects).</li>
<li>Septic shock (shown in the <a href="https://www.ncbi.nlm.nih.gov/pubmed/18654759">CAT trial</a> to be an adequate alternative to norepinephrine).  It seems to work especially well in patients with inappropriately low heart rate and/or low cardiac output, who likely have a poor sympathetic response to sepsis (more on this <a href="https://emcrit.org/pulmcrit/epinephrine-challenge-septic-shock/">here</a>).</li>
<li>At low doses (below 5-10 mcg/kg/min), the predominant effect is as an inotrope, so it can be used for patients with low-output cardiogenic shock.  Compared to dobutamine/milrinone, low-dose epinephrine has a touch of alpha-activity which will tend to prevent hypotension.</li>
<li>Push-dose epinephrine is useful for patients crashing from a variety of causes (e.g. <a href="https://emcrit.org/pulmcrit/epinephrine-atropine-bradycardia/">bradycardic peri-arrest</a>).  Epinephrine is generally a good choice for the nearly-dead patient.</li>
<li>First-line agent for anaphylaxis.   Note that epinephrine may be indicated for treatment for anaphylaxis even if the hemodynamics are stable (see <a href="https://emcrit.org/ibcc/anaphylaxis/"><em>IBCC anaphylaxis chapter</em></a>).</li>
</ul>
</li>
<li>How to titrate:  depends on clinical application.</li>
<li>Pro/Con
<ul>
<li>Epinephrine is a powerful drug with established efficacy in sepsis, also useful in bradycardia and cardiogenic shock.</li>
<li>The main concern is that at high doses for long periods of time, it may promote a stress cardiomyopathy.</li>
<li>It causes lactate production which isn't dangerous (may be physiologically <a href="https://emcrit.org/pulmcrit/understanding-lactate-in-sepsis-using-it-to-our-advantage/">beneficial</a>).  However, practitioners must be aware of this issue; otherwise they may senselessly chase lactate values.</li>
<li>Epinephrine causes a small decrease in potassium, which is generally not a problem.  Effects on potassium may be useful in patients with hyperkalemia and bradycardia (<a href="https://emcrit.org/pulmcrit/brash-syndrome-bradycardia-renal-failure-av-blocker-shock-hyperkalemia/">BRASH syndrome</a>).</li>
</ul>
</li>
</ul>
<h5 id="dopamine" tabindex="-1"><strong>dopamine</strong></h5>
<ul>
<li>Mechanism/physiology
<ul>
<li>Dopamine hits a variety of receptors at different dose ranges (“dirty” drug).</li>
<li>It's often difficult to figure out what it is doing to your patient. For example, low-dose dopamine can actually cause <em>hypotension</em> (due to a predominant effect of vasodilation), which can make it difficult to wean off the dopamine.</li>
</ul>
</li>
<li>Reasons dopamine should be abandoned:
<ol>
<li>Dopamine increases mortality in RCTs:   Dopamine increased mortality compared to norepinephrine in the subgroup of patients with cardiogenic shock (<a href="https://www.ncbi.nlm.nih.gov/pubmed/20200382">De Backer 2010</a>).  It also increased mortality compared to epinephrine among septic children (<a href="https://www.ncbi.nlm.nih.gov/pubmed/26323041">Ventura 2015</a>).</li>
<li>It's often impossible to figure out what dopamine is doing (given the variety of different effects at different doses in different patients).   This makes it impossible to titrate in any rational fashion (up-titration may cause dopamine to function via a different mechanism entirely).</li>
<li>Dopamine has unique adverse endocrine effects.</li>
<li>Dopamine may directly stimulate diuresis via action on dopamine-receptors, thereby falsely suggesting that renal perfusion is adequate.</li>
<li>There is a relatively high risk of tissue necrosis if it extravasates.</li>
<li>Better agents exist:  there is nothing dopamine does that can't be achieved with the use of norepinephrine and/or epinephrine.</li>
<li>Dopamine may cause greater malperfusion of the gut compared to norepinephrine.</li>
</ol>
</li>
</ul>
<h3 id="peripheral-pressors" tabindex="-1">peripheral pressors</h3>
<h5 id="peripheral-iv-line" tabindex="-1"><strong>peripheral IV line</strong></h5>
<ul>
<li>Hemodynamic stabilization should never wait until central access is obtained.  Thus, peripheral vasopressors should be started immediately if the blood pressure or perfusion is inadequate.</li>
<li>Norepinephrine is safe for short periods of time through a large peripheral vein.  Ongoing peripheral infusion also appears safe, but this should ideally be done within the context of a well-designed protocol involving frequent monitoring of the extremity and preparation for management of extravasation reaction (more on this <a href="https://emcrit.org/emcrit/peripheral-vasopressors-extravasation/">here</a>).  Ongoing infusion should be <em>avoided</em> in deep ultrasound-guided peripheral IVs, where it may be impossible to monitor the tissue surrounding the end of the IV cannula.</li>
<li>Phenylephrine and epinephrine have <em>not</em> been reported to cause tissue necrosis.  Peripheral infusion of these agents appears to be generally safe, although this should still ideally be done via a well-functioning cannula proximal to the wrist (more on this <a href="https://emcrit.org/pulmcrit/phenylephrine-epinephrine-central-access/">here</a>).</li>
<li>Vasopressin should arguably be avoided for peripheral administration, because if it extravasates there is no vasodilatory agent which can counteract its action.</li>
</ul>
<h5 id="midline-catheter" tabindex="-1"><strong>midline catheter</strong></h5>
<ul>
<li>These are catheters placed in the arm, similar to a PICC, but shorter (typically 10-20 cm in length, terminating before the shoulder).</li>
<li>Clinician-placed midlines are evolving as an alternative to either ultrasound-guided peripheral IVs or central lines.</li>
<li>This is a rapidly emerging topic.  Overall, vasopressor administration via midline catheters appears to be safe.</li>
<li>More on midline catheters:  see <a href="https://emcrit.org/emcrit/midlines-1/">EMCrit RACC Midlines part 1</a> &amp; <a href="https://emcrit.org/emcrit/midlines-part-2/">part 2</a>.</li>
</ul>
<h3 id="midodrine" tabindex="-1">midodrine</h3>
<h5 id="basics" tabindex="-1"><strong>basics</strong></h5>
<ul>
<li>Oral alpha-1 agonist, which acts as a pure vasopressor.</li>
</ul>
<h5 id="more-common-clinical-indications-in-critical-care%3A" tabindex="-1"><strong>more common clinical indications in critical care:</strong></h5>
<ul>
<li>Cirrhosis &amp; hepatorenal syndrome
<ul>
<li>Midodrine is a component of oral therapy for hepatorenal syndrome.</li>
<li>Some evidence suggests that <em>ongoing</em> midodrine therapy in patients with cirrhosis may support renal perfusion (given that these patients suffer from chronic vasodilation).</li>
</ul>
</li>
<li>Accelerated weaning from vasopressors
<ul>
<li>The MIDAS trial suggests that midodrine is <em>not</em> effective at accelerating the weaning off IV vasopressors among most ICU patients (more on the MIDAS trial <a href="https://www.thebottomline.org.uk/summaries/midas/"><em>here</em></a>).</li>
<li>Currently, best available evidence indicates that midodrine should <em>not</em> be used to hasten weaning off vasopressor infusions among non-cirrhotic patients.</li>
</ul>
</li>
</ul>
<h5 id="dose" tabindex="-1"><strong>dose</strong></h5>
<ul>
<li>The usual starting dose is 10 mg PO q8hr.  <em>Make sure the drug is dosed q8hr and not “three times daily with meals,” which is what the computer may default to.</em></li>
<li>Dose range is 5-40 mg q8hr (26953217).</li>
<li>Midodrine is cleared by the kidney, so exercise caution in renal dysfunction.</li>
</ul>
<h5 id="contraindications%2Fcautions" tabindex="-1"><strong>contraindications/cautions</strong></h5>
<ul>
<li>Reflex bradycardia can occur.</li>
</ul>
<h3 id="methylene-blue" tabindex="-1">methylene blue</h3>
<h5 id="mechanisms-of-action" tabindex="-1"><strong>mechanisms of action</strong></h5>
<ul>
<li>(1) Methylene blue causes vasoconstriction by inhibiting nitric oxide synthase.
<ul>
<li>This is a potentially dangerous way to increase blood pressure, because it could potentially impair microvascular perfusion.</li>
<li>Historically, a nitric oxide synthesis inhibitor was shown to increase mortality in septic shock (<a href="https://www.ncbi.nlm.nih.gov/pubmed/14707556">14707556</a>).</li>
</ul>
</li>
<li>(2) Methylene blue inhibits the conversion of guanine triphosphate to cGMP (an intracellular signaling molecule which increases vasodilation).</li>
<li>(3) Methylene blue may be able to accept electrons from NADH and transfer them to cytochrome C in the mitochondria, thereby <em>bypassing</em> parts of the electron transport chain.  This could restore mitochondrial function in some situations where parts of the electron transport chain are dysfunctional, for example metformin toxicity (28840449).</li>
</ul>
<h5 id="more-common-indications" tabindex="-1"><strong>more common indications</strong></h5>
<ul>
<li>Refractory vasoplegic shock of any etiology.
<ul>
<li><em>Especially</em> following cardiothoracic surgery.</li>
<li>Possibly also:  septic shock, anaphylaxis.</li>
</ul>
</li>
<li>Metformin poisoning</li>
</ul>
<h5 id="dosing" tabindex="-1"><strong>dosing</strong></h5>
<ul>
<li>#1)  Test dose of 2 mg/kg infused over 15 minutes.
<ul>
<li>If no response, then try another medication or treatment strategy.</li>
<li>If response seen, then consider initiating an infusion…</li>
</ul>
</li>
<li>#2)  Infusion:
<ul>
<li>Dose range from 0.25 – 2 mg/kg/hour.</li>
<li>May be continued for up to 48-72 hours.  Wean off when hemodynamics improve.</li>
</ul>
</li>
</ul>
<h5 id="potential-adverse-effects-%2F-contraindications" tabindex="-1"><strong>potential adverse effects / contraindications</strong></h5>
<ol>
<li>Inhibition of cGMP may increase pulmonary vascular resistance, thereby impairing right ventricular function and impairing oxygenation.  This may be more of a problem at higher doses.</li>
<li>High levels of methylene blue can interfere with pulse oximetry (a problem mostly when giving the bolus dose).</li>
<li>Methylene blue can act as an oxidizing agent at high doses (e.g. &gt;7 mg/kg).  This may cause methemoglobinemia.  In patients with G6PD deficiency, this could also cause hemolytic anemia.</li>
<li>Methylene blue inhibits monoamine oxidase A (MAO), thereby increasing brain serotonin levels.  This could cause serotonin syndrome in the presence of other serotonergic agents.</li>
<li>Methylene blue may inhibit CYP enzyme metabolism, leading to accumulation of some medications (e.g. digoxin, warfarin, fentanyl).</li>
<li>Methylene blue is contraindicated in pregnancy (due to a potential for placental vasoconstriction and fetal hypoxemia).</li>
</ol>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        <nav class="toc" >
        <ul><li><a href="#overview">Overview</a><ul><li><a href="#inodilators">inodilators</a></li><li><a href="#pure-vasopressors">pure vasopressors</a></li><li><a href="#inopressors">inopressors</a></li><li><a href="#peripheral-pressors">peripheral pressors</a></li><li><a href="#midodrine">midodrine</a></li><li><a href="#methylene-blue">methylene blue</a></li></ul></li></ul>
      </nav>
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/cardiology with critical care/" class="peer">Cardiology with Critical Care</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="cardiology-with-critical-care" tabindex="-1">cardiology with critical care</h1>
<ul>
<li>related: <a href="/wiki/notes/Cardiology/">Cardiology</a>, <a href="/wiki/notes/ICU/">ICU</a></li>
</ul>
<h2 id="mechanical-ventilation" tabindex="-1">mechanical ventilation</h2>
<ul>
<li>Increasing oxygenation
<ul>
<li>increase FiO2</li>
<li>Increase PEEP, I:E ratio (increase alveolar recruitment)</li>
<li>Decrease O2 consumption (increase sedation, analgesia, paralysis, synchrony)</li>
</ul>
</li>
<li>Minute Ventilation = RR X tidal volume</li>
</ul>
<h3 id="modes-of-ventilation" tabindex="-1">modes of ventilation</h3>
<ul>
<li>AC: assist control. Specified volume or pressure for all breaths regardless whether patient or machine initiates breath
<ul>
<li>default</li>
</ul>
</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/ICU/" class="peer">ICU</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="icu" tabindex="-1">ICU</h1>
<ul>
<li>related: <a href="/wiki/notes/vasopressors/">vasopressors</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20210917122307.png" alt=""></p>
<ul>
<li><a href="/wiki/notes/enteral%20feeding/">enteral feeding</a></li>
<li><a href="/wiki/notes/lactic%20acidosis/">lactic acidosis</a></li>
<li><a href="/wiki/notes/capnography/">capnography</a></li>
</ul>
<h2 id="airway" tabindex="-1">Airway</h2>
<ul>
<li><a href="/wiki/notes/The%20Walls%20Manual%20of%20Emergency%20Airway%20Management/">The Walls Manual of Emergency Airway Management</a></li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
